Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5150314 | 0.81 | ABCB1 (0.37) | — | |
| SCHEMBL3295186 | 0.78 | HTR2C (0.40) | — | |
| SCHEMBL7123630 | 0.74 | DDB1 (0.32) | — | |
| SCHEMBL19477952 | 0.73 | NR1H2 (0.40) | NR1H2CHRM2CHRM1CHRM3EPHX2 | |
| SCHEMBL19477955 | 0.73 | NR1H2 (0.40) | NR1H2CHRM2CHRM1CHRM3EPHX2 | |
| SCHEMBL21274860 | 0.72 | CHRM2 (0.44) | NR1H2CHRM2CHRM1CHRM3EPHX2 | |
| SCHEMBL20973202 | 0.72 | CHRM2 (0.44) | NR1H2CHRM2CHRM1CHRM3EPHX2 | |
| SCHEMBL26916063 | 0.72 | CHRM2 (0.44) | NR1H2CHRM2CHRM1CHRM3EPHX2 | |
| SCHEMBL2386059 | 0.72 | — | — | |
| SCHEMBL28036906 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1889845-A1 | NOVEL PLEUROMUTILIN DERIVATIVES | SmithKline Beecham P.L.C. (GB) | 2008-02-20 | — | — | EP | disclosed |
| EP-1538150-B1 | NOVEL PLEUROMUTILIN DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 2007-06-27 | — | — | EP | disclosed |
| US-7160907-B2 | Pleuromutilin derivatives | SMITHKLINE BEECHAM P.L.C. (GB) | 2007-01-09 | — | — | US | disclosed |
| EP-1538150-A1 | NOVEL PLEUROMUTILIN DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 2005-06-08 | — | — | EP | disclosed |
| EP-1351959-B1 | NOVEL PLEUROMUTILIN DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 2005-06-01 | — | — | EP | disclosed |
| US-6900345-B2 | Pleuromutilin derivatives | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-05-31 | — | — | US | disclosed |
| US-20050096357-A1 | Novel pleuromutilin derivatives | SMITHKLINE BEECHAM P.L.C. | 2005-05-05 | — | — | US | disclosed |
| US-20040024059-A1 | Novel pleuromutilin derivatives | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-02-05 | — | — | US | disclosed |
| US-20030216374-A1 | Antibiotic oxazolidinone derivatives | SYNGENTA LIMITED (GB) | 2003-11-20 | — | — | US | disclosed |
| US-6605630-B1 | Active against drug resistant gram positive pathogens | SYNGENTA LIMITED (GB) | 2003-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024059-A1 | Novel pleuromutilin derivatives | PLEC, MLNR, FABP2 | NR1H2 3640/4885CHRM2 4500/4885CHRM1 4667/4885 |
| US-20050096357-A1 | Novel pleuromutilin derivatives | FABP2, PLEC, MLNR | NR1H2 3511/4885CHRM2 4594/4885CHRM1 4745/4885 |
| US-20030216374-A1 | Antibiotic oxazolidinone derivatives | OXA1L, HRH1, OGDH | NR1H2 43/4885CHRM2 3900/4885CHRM1 2677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.